Share

Optimizing doses and screening accuracy in breast tomosynthesis

Mammograph at the Georges Pompidou European Hospital. © CEA
Breast tomosynthesis, a novel 3D-imaging method, represents the latest technological leap in mammography for breast cancer screening. The use of new X-ray radiation qualities demands it demands new dosimetric benchmarks and equipment quality control protocols to precisely quantify and optimize delivered radiation doses.

Metrological evaluation of these advanced mammography systems requires rigorous characterization of the clinical X-ray beams used. To achieve this, our Henri Becquerel National Laboratory (LNHB-MD) replicated the beam configurations used at the Georges Pompidou European Hospital (HEGP).

Through sophisticated analysis and correction procedures that address escape effects caused by fluorescence and pile-up effects caused by high counting rates, the team reproduced clinical spectra with exceptional precision. These beams now enable the LNHB-MD to calibrate clinical radiameters, ensuring accurate monitoring of patient exposure levels during diagnostic exams.

This makes it possible to balance diagnostic image quality with the varying radiation dose requirements of individual breast anatomy.

This research is part of the national metrology program, a collaboration with HEGP and a doctoral thesis aimed at automating the measurement of mean glandular dose, the indicator for optimizing patient exposure. This tool will enhance dose traceability during mammograms and improve the safety of tomosynthesis in breast cancer screening.

Chiffres clés

2,3

million women were diagnosed with breast cancer and

670 000

deaths globally. Source: WHO website

Tomography invites us to rethink the metrological traceability chain, from defining the dosimetric quantity to the measurement methods.

Rebecca Cabean

Jean-Marc Bordy

DIRECTOR OF RESEARCH — CEA-List

By improving our knowledge of the doses delivered to patients, this collaboration helps make using breast tomosynthesis for breast cancer screening safer.

Isabelle Fitton & Claire Van Ngoc Ty

MEDICAL PHYSICISTS — GEORGES POMPIDOU EUROPEAN HOSPITAL, APHP

Contributed to this article:

  • Jean-Marc Bordy, research director at CEA-List
  • Isabelle Fitton & Claire Van Ngoc Ty, medical physicists at the Georges Pompidou European Hospital (AP-HP)